Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) may experience acute relapses that are nonresponsive (20-35%) to...
Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials
Background: Ublituximab, a novel monoclonal antibody, targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced...